Biosimilars in Action at ASH 2018

Posted by Prateek Yadav on Dec 21, 2018 9:12:11 AM

Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.

At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.

Here are our top three takeaways from this year’s event:


>
Read More

Increasing Collaboration to Lower System Cost and Deliver Value: Insights From ASH 2016

Posted by Christina Corridon on Dec 22, 2016 11:13:31 AM

Meadow Green co-wrote this post with Christina Corridon.

In addition to its coverage on value in cancer treatments, the 2016 American Society of Hematology (ASH) Annual Meeting also featured sessions that highlighted how players in a rapidly evolving healthcare delivery ecosystem can collaborate to deliver value and lower system costs.


>
Read More